Annexin A1在紫杉醇耐药卵巢癌中的表达及其临床意义

目的：探讨Annexin A1(ANXA1)在卵巢癌紫杉醇耐药细胞及组织中的表达，分析其与卵巢癌紫杉醇耐药及临床病理特征之间的关系。方法：采用Western 印迹及实时PCR方法检测卵巢癌紫杉醇耐药细胞株(SKOV3/Taxol-25)及敏感细胞株(SKOV3)中ANXA1的表达差异；采用免疫组织化学SP法检测42例卵巢癌标本中ANXA1蛋白的表达情况，结合临床资料分析ANXA1表达水平与卵巢癌紫杉醇耐药及临床病理特征的关系。结果：耐药细胞株中ANXA1的表达明显低于敏感细胞株(P<0.05)；耐药组织中ANXA1蛋白阳性表达例数(14/20)明显少于敏感组织 (21/22，P<0.05)；而两组ANXA1蛋白表达的中强度阳性例数之间的差异也有统计学意义(P<0.01)；ANXA1蛋白的表达与卵巢癌组织类型、病理分级无关(P>0.05)，而与临床分期相关(P<0.05)。结论：ANXA1在卵巢癌紫杉醇耐药细胞及组织中低表达，提示通过检测其表达情况可预测卵巢癌患者对紫杉醇化学治疗的敏感性。

Expression of Annexin A1 in paclitaxel-resistant ovarian carcinoma and its clinical significance

Objective: To investigate the correlation of Annexin A1 (ANXA1) expression with paclitaxelresponse and clinicopathological features of ovarian carcinoma.Methods: The expression levels of ANXA1 in ovarian carcinoma SKOV3/Taxol-25 and SKOV3cell lines were detected by Western blot and real time-PCR. The expression of ANXA1 protein in42 specimens of ovarian carcinoma was examined by immunhistochemistry. The correlation ofANXA1 expression with paclitaxel response and clinicopathological features of ovarian carcinomawas analyzed.Results: The expression level of ANXA1 was significantly lower in SKOV3/Taxol-25 cell line thanthat in SKOV3 cell line (P<0.05). The positive specimens of ANXA1 expression in paclitaxel-resistanttissues (14/20) were significantly lower than those in the sensitive ones (21/22,P<0.05), and there was also a significant difference between the mild and the strong positivespecimens (P<0.01). The expression of ANXA1 protein showed no correlation with the type ofmophology and histological grade of ovarian cancer (P>0.05), but it was correlated with the clinicalstage(P<0.05).Conclusion: ANXA1 expression is downregulated in paclitaxel-resistant ovarian carcinoma, whichmight be a valuable predictor for paclitaxel susceptibility of ovarian carcinoma.